Baxalta (''Bax'' from the name of its former parent company; ''alta'' a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of

Takeda Pharmaceutical Company The is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 followin ...

Company history

Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aimed to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol (a German company) for 225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for 900 million. In August 2015,

Shire Plc Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was ...

made an unsolicited $30.6 billion stock offer for the company increasing the Baxalta share price over 16%. Baxalta investors would be set to receive 0.1687 of Shire's

American Depositary Receipt An American depositary receipt (ADR, and sometimes spelled ''depository'') is a negotiable security that represents securities of a foreign company and allows that company's shares to trade in the U.S. financial markets. Shares of many non-U.S ...

s for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3. This deal would create the largest global biotech company focused solely on rare diseases. In 2016 the company was acquired by Shire for $32 billion. Subsequently, Shire was acquired by

for $62 billion in January 2019.

References

Biopharmaceutical companies 2016 mergers and acquisitions Biotechnology companies of the United States Pharmaceutical companies established in 2015 Biotechnology companies established in 2015 Biotechnology companies disestablished in 2016 Pharmaceutical companies disestablished in 2016 Corporate spin-offs Baxter International {{Med-company-stub